CVI Alterations in FD: a Prospective, Multicenter, Observational Cohort Study

Recruiting

• Conditions: Fabry Disease, Cardiac Variant

• Registration Number: NCT06512571
• Lead Sponsor: China National Center for Cardiovascular Diseases

Brief Summary

Fabry disease (FD) is a rare X-linked lysosomal storage disorder caused by α-galactosidase A (GLA) gene mutations leading to reduced or undetectable α galactosidase A (α-Gal A) enzyme activity, resulting in progressive accumulation of globotriaosylceramide (GL3) and its deacylated form globotriaosylsphingosine (Lyso-GL-3) in multiple organs, causing neural, renal, cardiac, dermatological, gastrointestinal and ophthalmic manifestations, even leading to life-threatening complications. Cardiovascular and cerebrovascular complications (i.e. heart failure, stroke, etc.) or end-stage renal disease even premature death can be seen in severe cases. The life expectancy of male patients is reduced by 15\~20 years, while that of female patients is reduced by 6\~10 years.

The exact prevalence of FD is currently unknown. Based on an estimated prevalence of 1:60,000, there are approximately 23,000 affected FD patients in China. The clinical manifestations of FD are diverse and non-specific, which may lead to misdiagnosis in patients with non-typical clinical manifestations in the absence of a family history of FD. Cardiac involvement can be recognized in up to 68% patients with FD, significantly higher than in other organs, and the positive screening rate for FD in adults with unexplained left ventricular hypertrophy (LVH)/hypertrophic cardiomyopathy was 0.9%.

Cardiovascular disease is the leading cause of death in patients with FD cardiomyopathy (40.2%). The 2020 Expert Consensus Document on the Management of Cardiovascular Manifestations of Fabry Disease recommends early screening in patients with suspected LVH for early diagnosis. Therefore, strengthened screening strategy in high-risk patients with LVH will improve the diagnosis and treatment of FD in China.

Detailed Description

Not available

Study Timeline

• Status Verified: 2024-07
• Study First Submitted: 2024-07-16
• Study First Submitted QC: 2024-07-16
• Study First Posted: 2024-07-22
• Study Start: 2024-12-31
• Last Update Submitted: 2025-03-23
• Last Update Posted: 2025-03-26
• Primary Completion: 2026-12-30
• Study Completion: 2026-12-30

Recruitment & Eligibility

• Status: RECRUITING
• Sex: All
• Target Recruitment: 300

Inclusion Criteria

Patients to be enrolled in this study should fulfill all 3 criteria (a, b, and c) at screening:

1. Patients with a maximum myocardial wall thickness (left ventricular posterior wall or septum) of ≥13 mm at the end diastole on echocardiography;
2. At least two or more "warning signs" associated with FD ("warning signs" include cardiac "warning signs", extracardiac "warning signs", or family history)
3. Aged 18 years old or older;

cardiac "warning signs" of FD:

Concentric LVH or papillary hypertrophy or right ventricular hypertrophy on echocardiography

ECG abnormalities (eg, shortened PR interval, wide QRS complex, right bundle branch block, ST-segment depression, etc.)

Extra-cardiac "warning signs" of FD

Angiokeratomas

Acroparesthesia

Hypohidrosis

Premature stroke (<50 years of age)

Corneal verticillate

Renal impairment accompanied by proteinuria

Hearing loss

Family history

Family history of X-linked inherited disorder (renal disease or cardiac disease)

Exclusion Criteria

1. LVH patients with a clear etiology;
2. Combining any other clinical condition with a life expectancy less than 1 year;
3. Refuse to give informed consent or refuse to be followed-up.

Study & Design

• Study Type: OBSERVATIONAL
• Study Design: Not specified

Primary Outcome Measures

Name	Time	Method
Cardiovascular deaths	12 months	Including sudden cardiac death or equivalent events, heart failure-related death, stroke-related death and death from other cardiovascular causes.

Secondary Outcome Measures

Name	Time	Method
Heart failure	12 months	NYHA progression to level III/IV
Myocardial infarction	12 months	Including ST-segment elevation myocardial infarction and non-ST-segment elevation myocardial infarction
Stroke	12 months	Including ischemic stroke and hemorrhagic stroke
All-cause deaths	12 months	Death from all causes

Trial Locations

Locations (1)

Fuwai Hospital, National Centre for Cardiovascular Disease, Chinese Academy of Medical Sciences and Peking Union Medical College; 🇨🇳 Beijing, China